Volume | 7,297 |
|
|||||
News | - | ||||||
Day High | 8.1392 | Low High |
|||||
Day Low | 7.8617 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.89 | 7.8617 | 8.1392 | 7.80 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
82 | 7,297 | $ 7.94 | $ 57,956 | - | 1.3601 - 8.3487 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:23:40 | 800 | $ 8.005 | USD |
Aeterna Zentaris Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
39.24M | 4.86M | - | 4.5M | -16.55M | -3.41 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aeterna Zentaris News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.14 | 8.3487 | 1.96 | 6.04 | 12,431 | 5.87 | 274.07% |
1 Month | 2.05 | 8.3487 | 1.95 | 2.93 | 13,635 | 5.96 | 290.49% |
3 Months | 1.78 | 8.3487 | 1.68 | 2.25 | 18,482 | 6.23 | 349.72% |
6 Months | 1.49 | 8.3487 | 1.45 | 2.13 | 15,981 | 6.52 | 437.25% |
1 Year | 3.05 | 8.3487 | 1.3601 | 2.30 | 12,683 | 4.96 | 162.46% |
3 Years | 0.9468 | 8.3487 | 0.1645 | 0.6580945 | 564,317 | 7.06 | 745.48% |
5 Years | 3.35 | 8.3487 | 0.1645 | 1.14 | 1,847,534 | 4.66 | 138.96% |
Aeterna Zentaris Description
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |